On 24 September 2021, the Permanent Mission of the Russian Federation to the United Nations (UN) and the World Health Organization co-hosted a special UN General Assembly virtual side event to review progress towards reaching global TB targets, advance multisectoral action and accountability, and discuss preparations for the 2023 UN High-Level Meeting on TB.

The World Health Organization (WHO)’s Global TB Program will conduct a post-graduate course on the latest WHO TB guidelines and recommendations on prevention, screening, diagnosis, treatment and care of TB. The course is organized as part of the 52nd Union World Conference on Lung Health on 28 September 2021.

On 30 September 2021, the World Health Organization (WHO)' Global TB Program will host a special #EndTB webinar on strengthening TB surveillance providing a global synthesis of findings and recommendations from national TB surveillance assessments and epidemiological reviews carried out between January 2013 and April 2020.

On 24 September 2021, the Permanent Mission of the Russian Federation to the United Nations (UN) and the World Health Organization will co-host a special UN General Assembly virtual side event to review progress towards reaching global TB targets, advance multisectoral action and accountability, and discuss preparations for the 2023 UN High-Level Meeting on TB.

The World Health Organization (WHO) Global TB Program is launching a second call for case studies of programmatic innovations to maintain and improve TB prevention and care in the context of the COVID-19 pandemic.

26 August 2021 | Geneva - A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced important updates to guidance on the management of tuberculosis (TB) in children and adolescents. This includes new recommendations on diagnostic options, treatment regimens, as well as treatment decision algorithms and optimal models of care for the delivery of child and adolescent TB services.

12 August 2021, Geneva | Currently the most widely used diagnostic tests for TB infection are the tuberculin skin test (TST) and interferon gamma release assays (IGRA). However, both classes of tests have limitations. Newer skin-based tests based on specific M. tuberculosis antigens (ESAT-6, CFP-10 and others) have been developed, these combine the simpler skin-test platform with the specificity of IGRA. Emerging evidence suggests that compared to IGRA, the tests may have similar specificity and provide more reliable results in children and in HIV-infected cohorts. However, the evidence has not been systematically reviewed.

10 August 2021 | Geneva - The World Health Organization (WHO) is launching its updated target product profile (TPP) for next-generation drug-susceptibility (DST) testing for M. tuberculosis at peripheral centres.

Abuja, 21 July, 2021 - Response to the coronavirus pandemic notwithstanding, data indicate that there has been an increase in annual tuberculosis (TB) case notification due to strategic intervention by  the  National Tuberculosis, Buruli Ulcer and Leprosy Control Program (NTBLCP), in collaboration with World Health Organization (WHO) and other stakeholders working on TB control and elimination in Nigeria.

The World Health Organization (WHO) is publishing a position statement on Innovative Clinical Trial Designs for Development of New TB Treatments. This document aims to support TB regimen development by highlighting key clinical trial characteristics to help advance novel therapies. It summarises key innovations in TB clinical trial designs, ranging from pharmacokinetic-pharmacodynamic (PK-PD) modelling and new advances in biomarker development to the value of novel clinical trial design methodologies and post-licensure observational studies.